75 related articles for article (PubMed ID: 26044890)
1. Effect of combined deferasirox and 5-azacytidine treatment on human leukemia cells in vitro.
Imanishi S; Takahashi R; Ohsuga M; Ohyashiki K; Ohyashiki JH
Ann Hematol; 2015 Sep; 94(9):1601-2. PubMed ID: 26044890
[No Abstract] [Full Text] [Related]
2. Synergistic inhibitory effects of deferasirox in combination with decitabine on leukemia cell lines SKM-1, THP-1, and K-562.
Li N; Chen Q; Gu J; Li S; Zhao G; Wang W; Wang Z; Wang X
Oncotarget; 2017 May; 8(22):36517-36530. PubMed ID: 28388554
[TBL] [Abstract][Full Text] [Related]
3. The oral iron chelator deferasirox induces apoptosis in myeloid leukemia cells by targeting caspase.
Kim JL; Kang HN; Kang MH; Yoo YA; Kim JS; Choi CW
Acta Haematol; 2011; 126(4):241-5. PubMed ID: 21951998
[No Abstract] [Full Text] [Related]
4. The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.
Lui GY; Obeidy P; Ford SJ; Tselepis C; Sharp DM; Jansson PJ; Kalinowski DS; Kovacevic Z; Lovejoy DB; Richardson DR
Mol Pharmacol; 2013 Jan; 83(1):179-90. PubMed ID: 23074173
[TBL] [Abstract][Full Text] [Related]
5. Deferasirox increases BU blood concentrations.
Sweiss K; Patel P; Rondelli D
Bone Marrow Transplant; 2012 Feb; 47(2):315-6. PubMed ID: 21460865
[No Abstract] [Full Text] [Related]
6. 5-azacytidine enhances efficacy of multiple chemotherapy drugs in AML and lung cancer with modulation of CpG methylation.
Füller M; Klein M; Schmidt E; Rohde C; Göllner S; Schulze I; Qianli J; Berdel WE; Edemir B; Müller-Tidow C; Tschanter P
Int J Oncol; 2015 Mar; 46(3):1192-204. PubMed ID: 25501798
[TBL] [Abstract][Full Text] [Related]
7. Inconsistent hepatic antifibrotic effects with the iron chelator deferasirox.
Sobbe A; Bridle KR; Jaskowski L; de Guzman CE; Santrampurwala N; Clouston AD; Campbell CM; Subramaniam VN; Crawford DH
J Gastroenterol Hepatol; 2015 Mar; 30(3):638-45. PubMed ID: 25168203
[TBL] [Abstract][Full Text] [Related]
8. Effect of histone deacetylase inhibitors trichostatin A and valproic acid on etoposide-induced apoptosis in leukemia cells.
Jasek E; Lis GJ; Jasinska M; Jurkowska H; Litwin JA
Anticancer Res; 2012 Jul; 32(7):2791-9. PubMed ID: 22753739
[TBL] [Abstract][Full Text] [Related]
9. Iron chelators induce autophagic cell death in multiple myeloma cells.
Pullarkat V; Meng Z; Donohue C; Yamamoto VN; Tomassetti S; Bhatia R; Krishnan A; Forman SJ; Synold TW
Leuk Res; 2014 Aug; 38(8):988-96. PubMed ID: 24998390
[TBL] [Abstract][Full Text] [Related]
10. Exjade (ICL 670): A new oral iron chelator.
Agarwal MB
J Assoc Physicians India; 2006 Mar; 54():214-7. PubMed ID: 16800349
[TBL] [Abstract][Full Text] [Related]
11. Iron chelation in the treatment of cancer: a new role for deferasirox?
Bedford MR; Ford SJ; Horniblow RD; Iqbal TH; Tselepis C
J Clin Pharmacol; 2013 Sep; 53(9):885-91. PubMed ID: 23740857
[TBL] [Abstract][Full Text] [Related]
12. Deferasirox shows in vitro and in vivo antileukemic effects on murine leukemic cell lines regardless of iron status.
Lee DH; Jang PS; Chung NG; Cho B; Jeong DC; Kim HK
Exp Hematol; 2013 Jun; 41(6):539-46. PubMed ID: 23415674
[TBL] [Abstract][Full Text] [Related]
13. Deferasirox: the new oral iron chelator.
Dubey AP; Sudha S; Parakh A
Indian Pediatr; 2007 Aug; 44(8):603-7. PubMed ID: 17827637
[TBL] [Abstract][Full Text] [Related]
14. The positive effect of deferasirox on erythropoiesis in a patient with a dual diagnosis of myelofibrosis and diffuse large B-cell lymphoma.
Kostos L; Chai KL; Tam CS; Bazargan A
Leuk Lymphoma; 2017 Nov; 58(11):2720-2723. PubMed ID: 28332891
[No Abstract] [Full Text] [Related]
15. Deferasirox removes cardiac iron and attenuates oxidative stress in the iron-overloaded gerbil.
Al-Rousan RM; Paturi S; Laurino JP; Kakarla SK; Gutta AK; Walker EM; Blough ER
Am J Hematol; 2009 Sep; 84(9):565-70. PubMed ID: 19650117
[TBL] [Abstract][Full Text] [Related]
16. Deferasirox reduces iron overload in a murine model of juvenile hemochromatosis.
Nick H; Allegrini PR; Fozard L; Junker U; Rojkjaer L; Salie R; Niederkofler V; O'Reilly T
Exp Biol Med (Maywood); 2009 May; 234(5):492-503. PubMed ID: 19234060
[TBL] [Abstract][Full Text] [Related]
17. The in-vitro antiproliferative effect of PRI-2191 and imatinib applied in combined treatment with cisplatin, idarubicin, or docetaxel on human leukemia cells.
Switalska M; Nasulewicz-Goldeman A; Opolska A; Maciejewska M; Kutner A; Wietrzyk J
Anticancer Drugs; 2012 Jan; 23(1):70-80. PubMed ID: 21934605
[TBL] [Abstract][Full Text] [Related]
18. Deferasirox decreases age-associated iron accumulation in the aging F344XBN rat heart and liver.
Arvapalli RK; Paturi S; Laurino JP; Katta A; Kakarla SK; Gadde MK; Wu M; Rice KM; Walker EM; Wehner P; Blough ER
Cardiovasc Toxicol; 2010 Jun; 10(2):108-16. PubMed ID: 20229123
[TBL] [Abstract][Full Text] [Related]
19. Increased serum hepcidin levels during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndrome.
Ghoti H; Fibach E; Westerman M; Gordana O; Ganz T; Rachmilewitz EA
Br J Haematol; 2011 Apr; 153(1):118-20. PubMed ID: 21332711
[TBL] [Abstract][Full Text] [Related]
20. Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia.
Taher AT; Temraz S; Cappellini MD
Expert Rev Hematol; 2013 Oct; 6(5):495-509. PubMed ID: 24083402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
